Peptide-MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices

Area of Science:

• Immunology
• Nanotechnology
• Biomedical Engineering

Background:

• Autoimmune diseases involve aberrant immune responses.
• Nanoparticles (NPs) offer potential as platforms for therapeutic interventions.
• Ligand-multimerization platforms can activate specific cellular receptors.

Purpose of the Study:

• To define engineering principles for biologically active nanoparticles.
• To develop safe and stable nanoparticle formulations for therapeutic use.
• To investigate nanoparticle interactions with T cells for autoimmune disease treatment.

Main Methods:

• Synthesized nanoparticles coated with peptide-major histocompatibility complexes (pMHC).
• Investigated the impact of pMHC intermolecular distance on T cell activation.
• Visualized nanomedicine-T cell interactions using microscopy.
• Assessed nanoparticle toxicity in zebrafish embryos and in vivo studies.

Main Results:

• pMHC-coated nanoparticles (pMHC-NPs) blunted autoimmune responses by promoting regulatory T cell differentiation and expansion.
• Nanoparticle triggering properties depend on pMHC intermolecular distance.
• Sustained assembly of large antigen receptor microclusters on T cells was observed.
• No off-target toxicity was detected in zebrafish embryos; compounds were rapidly cleared.

Conclusions:

• Engineering principles for pMHC-NPs were defined, impacting biological activity.
• Safe and stable nanomedicines were synthesized for potential autoimmune disease therapy.
• Nanotechnology provides a platform to re-program in vivo cellular responses.
• This work supports the development of ligand-based NP formulations for immune modulation.